United States· US:61755-005_9e18f393-aea5-48ef-8ac9-7d523f0badc0
EYLEA
A aflibercept product containing aflibercept, registered in United States by Regeneron Pharmaceuticals, Inc.. The same ATC class is registered in 11 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Aflibercept is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XX44 (aflibercept), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 7 of them publish a price we can compare per daily dose
Aflibercept · ATC L01XX44
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- AFLIBERCEPT
- Manufacturer
- Regeneron Pharmaceuticals, Inc.
- Country
- United States (US)
- ATC code
- L01XX44
- ATC class
- Aflibercept
- Defined daily dose
- 20 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc1161755-005-01
- ndc1161755-005-02
- ndc1161755-005-54
- ndc1161755-005-55
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
70 interactions on record for aflibercept.
Graded by severity as the source publishes them — 29 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aflibercept · interactions on record
70 records
- 29 severe
- 41 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Aflibercept in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FinlandAfivegSTADA Arzneimittel AG
- CzechiaAFIVEGSTADA Arzneimittel AG, Bad Vilbel
- BelgiumAfiveg 40 mg/mlStada Arzneimittel
- SwedenAfiveg 40 mg/ml Injektionsvätska, lösningSTADA Arzneimittel AG
- IcelandAfivegSTADA Arzneimittel AG
- SpainAFQLIR 40 MG/ML SOLUCION INYECTABLE EN JERINGA PRECARGADASandoz Gmbh
- NetherlandsAfiveg 40 mg/ml oplossing voor injectieStada Arzneimittel AG
- IrelandAfiveg 40 mg/mL solution for injectionStada Arzneimittel AG
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- United Kingdom (Northern Ireland) · Vgenfli
- Iceland · Afiveg, Afqlir
- Liechtenstein · Afiveg, Afqlir
- Norway · Afiveg, Afqlir
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dc6f3576-ca92-4fbc-ae51-c2c71cdd4598 GET /v1/drugs/dc6f3576-ca92-4fbc-ae51-c2c71cdd4598?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVITREAL",
"source": "ndc",
"strength": "40",
"substance": "AFLIBERCEPT",
"productndc": "61755-005",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125387",
"marketing_category": "BLA"
}See everything about aflibercept.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.